May 14th 2024
The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Bioimpedance Spectroscopy Can Help Prevent Clinical Lymphedema
May 12th 2018Several breast cancer treatment programs are reporting substantially less clinical lymphedema, particularly among patients at high risk after axillary dissection, radiation, or taxane-based chemotherapy, crediting their use of preclinical detection using bioimpedance spectroscopy (BIS).
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
April 20th 2018BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
NCCN Guidelines on Breast Cancer Impact Clinical Applications of Radiation Therapy
April 20th 2018The National Comprehensive Cancer Network (NCCN) guidelines on breast cancer now allow physicians to pinpoint the women who are most likely to benefit from post-mastectomy radiation using the latest targeted testing techniques.
Endocrine Therapy May Eliminate Need for Surgery or Chemotherapy for Some Breast Cancer Patients
March 15th 2018Endocrine therapy can reduce tumor size in patients with ER-positive breast cancer. It can even help some patients avoid chemotherapy or even surgery. Deciding how long to continue this therapy can be tricky though.
Ribociclib Benefits Premenopausal Women with Advanced Breast Cancer
March 10th 2018Ribociclib (Kisqali) improves progression-free survival (PFS) in pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer. These results, shared at 2018 Miami Breast Cancer Conference, were sustained across patient subgroups.
Liquid Biopsy Use in Metastatic TNBC Demonstrates Prognostic Potential
March 2nd 2018Predicting survival outcomes for patients with metastatic triple-negative breast cancer (mTNBC) is now possible using liquid biopsy, according to results from a retrospective study published in the Journal of Clinical Oncology.
FDA Approves Abemaciclib for Frontline Treatment of HR+/HER2- Advanced Breast Cancer
February 27th 2018Based on data from the phase III MONARCH 3 trial, the FDA has approved abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
Younger Cancer Survivors Put Themselves at Risk When They Fail to Seek Follow-Up Care
February 19th 2018Many adolescent and young adult (AYA) survivors of cancer end up "lost to follow-up," according to recent research. Nurses charged with patient education should take heed, and be sure to stress the importance of follow-up care to their AYA patients and their families.
Patient Navigation Initiative Takes Aim at Health Disparities
February 12th 2018Patient navigation is playing an increasingly vital role in guiding patients with breast cancer through the maze of the American healthcare system. The Patient Navigation Initiative is a pioneering project of Susan G. Komen of Greater New York City focused on helping women overcome barriers to care, which leads to improved outcomes.
Beyond BRCA: Gene Mutations in Breast Cancer
February 7th 2018In just over 5 years, the growth and development in the field of breast cancer have been astronomical. Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine, discusses the recent explosion of knowledge about non-BRCA genes, and the significant progress in therapies targeted to BRCA mutation carriers.